NYSE: MDT · Medical Devices
Medtronic (MDT) fair value: undervalued or overvalued?
As of 14 Nov 2026, Faircurve's model values Medtronic (MDT) at $100.47 a share. The stock last closed at $102.88, which puts the model's fair value 2.3% below the price. On the model's bands that reads as Fairly valued.
Revalued . Price is the close of 16 Nov 2026. Medtronic Plc.
The report adds the live price, the chart against the range the options market prices, the next earnings date and the analysts' consensus. No account needed.
This week, in three parts
What happenedThe run of 14 Nov 2026 moved the fair value from $99.40 to $100.47 (+1.1%). The stock's own trading multiple rose with its price, and the fair value follows it in part: most of the move.
What the model makes of itThe price of $102.88 is 2.3% above it: Fairly valued, on a high evidence grade.
What's nextReports on 24 Nov 2026. Options expiring after the report price a move of about 5% either way. The next weekly run is on Saturday 21 Nov 2026.
What price range does the model give MDT?
The calibrated range for MDT over 63 trading days is $92.91 to $114.51. It sits around the last close, and its width comes from the volatility that MDT's own options imply (31% a year), calibrated weekly against realised prices (n = 8,038 past valuations, refreshed 14 Nov 2026). Ranges built this way held the price 60% of the time at this horizon. The fair value is the model's opinion and rides beside the range. It is not the centre of it.
The model's own simulated range, from the 20th to the 80th percentile of its runs, is $81.81 to $120.93. In 45% of the simulations the fair value came out above the price the model ran on.
Faircurve Insights · 14 Nov 2026
Medtronic plc is a leading global medical technology enterprise. It invents, develops, manufactures and distributes an extensive range of device-based medical therapies.
On 14 Nov 2026 Faircurve's model gave a fair value of $100.47 a share, the midpoint of 2,000 simulations. The previous run, on 7 Nov 2026, gave $99.40, so the fair value moved +1.1%. In the model's own words, the stock's own trading multiple rose with its price, and the fair value follows it in part: most of the move. The calibrated range over 63 trading days is $92.91 to $114.51. It is built from the volatility the stock's own options imply, calibrated weekly against realised prices. Ranges built this way held the price 60% of the time at this horizon. The evidence grade is High. The grade covers how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It does not say whether the fair value is right.
The model's overall quality score is 41 out of 100, a composite of six factors scored against comparable companies. Stability scores highest at 100, with five-year EBITDA margin downside volatility of 0.8 pts against a peer median of 2.0 pts. Earnings quality scores lowest at 17, with FCF to net income of 1.17x against a peer median of 1.26x. Profitability scores 38, with ROIC of 7.0% against a peer median of 9.5%. The model compares the company with Stryker Corporation, Abbott Laboratories, Boston Scientific Corporation, Edwards Lifesciences Corporation, GE HealthCare Technologies Inc., DexCom, Inc. and Zimmer Biomet Holdings, Inc., each of which has a fair value of its own on the site.
Written from the figures on this page for the 14 Nov 2026 valuation and checked by rule before publishing: every number is one printed here, no forecast, no instruction. The price, the gap and the verdict are the page's own and change daily. Not a recommendation.
The Global Pulse
Faircurve's note after each US session, in your inbox. No account needed.
When does MDT report earnings, and how has the stock reacted?
Medtronic's next earnings report is scheduled for 24 Nov 2026. Companies can move their dates.
Options prices on 16 Nov 2026 imply a move of about 5.3% in either direction through the nearest expiry, about 10 days out, a window that includes the report. That is the size the market is pricing, not a direction. MDT's 30 day implied volatility works out to about 8.9% over one month.
Around its last 8 reports: what the options market priced, and what followed
Each move runs from the last close before the report to the first close after it, so it covers companies that report before the open and after the close. The median size across MDT's last 8 reports, ignoring direction, was 4.1%.
What the options market has priced for a month's move in MDT
How does MDT score on business quality?
Medtronic's overall quality score is 41 out of 100. Each factor below is a score against comparable companies, not a percentile of the metric beside it.
| Factor | Score (0 to 100) | Headline measure | Peer median |
|---|---|---|---|
| ProfitabilityReturn on invested capital against the peer group, with a bonus for an improving trend. | 38 | 7.0%ROIC | 9.5% |
| Earnings qualityHow much of reported profit is cash: free cash flow to net income, and the accrual ratio (the share of earnings that is not cash). | 17 | 1.17xFCF / net income | 1.26x |
| Growth qualityTrailing revenue growth, forward growth from consensus, and the direction of analysts' rating changes. | 49 | 8.4%Revenue growth, trailing | 9.9% |
| Capital disciplineReinvestment efficiency (capital spending per unit of revenue) and net buybacks. | 33 | 0.9%Net buybacks / market value | 0.5% |
| Balance sheetNet debt to EBITDA and interest coverage. | 33 | 2.60xNet debt / EBITDA | 1.98x |
| StabilityDownside volatility of the EBITDA margin over the last five years. | 100 | 0.8 ptsEBITDA margin downside volatility, 5y | 2.0 pts |
How does MDT compare with similar companies?
The companies in medical devices closest to Medtronic in market value, each on the same model and the same date.
| Company | Last close | Model fair value | Gap | Model verdict |
|---|---|---|---|---|
| SYK Stryker Corporation | $310.72 | $275.49 | -11.3% | Fairly valued |
| ABT Abbott Laboratories | $107.45 | $106.73 | -0.7% | Fairly valued |
| BSX Boston Scientific Corporation | $43.69 | $52.05 | +19.1% | Undervalued |
| EW Edwards Lifesciences Corporation | $107.11 | $88.12 | -17.7% | Overvalued |
| GEHC GE HealthCare Technologies Inc. | $82.96 | $90.14 | +8.7% | Fairly valued |
| DXCM DexCom, Inc. | $81.61 | $73.84 | -9.5% | Fairly valued |
| ZBH Zimmer Biomet Holdings, Inc. | $101.41 | $120.99 | +19.3% | Undervalued |
| GKOS Glaukos Corporation | $244.88 | $228.07 | -6.9% | Data under review |
What the comparable companies' multiples alone would give for MDT, the peer-implied price, is $92.30 a share on this run. The fair value weighs that against the company's own multiple.
Medtronic at a glance
Medtronic plc is a leading global medical technology enterprise that invents, develops, manufactures, and distributes an extensive range of device-based medical therapies.
- Market value
- $131.6B
- Sector
- Healthcare
- Industry
- Medical Devices
- Revenue expected, next twelve months
- $39.7B
- Consensus revenue growth, next fiscal year
- +7.4%
- Analysts with estimates
- 17
- Beta to the US market
- 0.03
- First valued by Faircurve
- 1 May 2026
At the close of 16 Nov 2026, 56.8% of the 1,085 graded US stocks the model covers traded below the model's fair value. MDT was not among them.
How the fair value is worked out: the model prices Medtronic on the value of the whole business, debt included, against the operating profit analysts expect next year (forward EV/EBITDA), runs 2,000 simulations across its inputs and takes the midpoint. The full method is documented here.
What changed in the latest valuation?
On 7 Nov 2026 the model's fair value for MDT was $99.40. As of 14 Nov 2026 it is $100.47, a change of +1.1%. The stock's own trading multiple rose with its price, and the fair value follows it in part: most of the move. The model revalues every stock it covers each week, and again after an earnings report.
Questions about Medtronic's valuation
Is Medtronic stock undervalued or overvalued?
On Faircurve's model, MDT reads as Fairly valued as of 14 Nov 2026. The model's fair value is $100.47 a share against a last close of $102.88, a gap of -2.3%.
What is MDT's fair value?
$100.47 a share as of 14 Nov 2026, the midpoint of 2,000 simulations. The model's own 20th to 80th percentile range is $81.81 to $120.93.
What price range does the model give MDT?
$92.91 to $114.51 over 63 trading days. Ranges built this way held the price 60% of the time across 8,038 past valuations, refreshed 14 Nov 2026.
When does Medtronic report earnings next?
The next report is scheduled for 24 Nov 2026. Companies can move their dates.
How much has MDT moved on past earnings reports?
Across its last 8 reports the median two session move was 4.1%, ignoring direction. The largest was +11.1% around the report of 3 Jun 2026.
How confident is the model in this valuation?
The model's evidence grade for MDT is high. The grade looks at how complete the inputs are, how many comparable companies there are and how closely they agree, and how wide the range of outcomes is. It is not a probability that the fair value is right, or that the price reaches it.
The model's own ideas on MDT
The model holds no idea open on MDT today. Signed-in readers see the rule each idea runs on, the floor and the exit level the model set and its time limit, and the model's closed ideas on MDT with their outcomes. A free account is enough.